Complete and durable remission in a patient with brain metastasis from gastric cancer treated with SRS followed by RC48 plus camrelizumab after progression on chemo-immunotherapy: a case report and literature review
Background Brain metastasis from gastric cancer carries a dismal prognosis, with median overall survival of only 3–6 months. Patients who progress on immune checkpoint inhibitor (ICI)-containing regimens have limited salvage options. HER2-low expression (IHC 1+ or IHC 2+/FISH-negative), historically excluded from anti-...